Sign in
CompletedNo phase

Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy

Key facts

Who runs it
Chiang Mai University
Where
Thailand1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
300 people enrolled
Started
1 Mar 2025
Ended
1 Mar 2026
Type of study
Observational, 2 groups
Treatments tested
  • exposure to Hydroxyethyl Starch (HES) Voluven® or Volulyte® 130/0.4
Record updated
17 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Inclusion CriteriaTo be included in the study, participants must meet all of the following requirements:Age: Patients must be at least 18 years old; Diagnosis: Patients must be diagnosed with a meningioma. Tumor Size: The tumor must be classified as "giant," defined as having a diameter of 5 cm or larger as seen on a CT scan; Surgery Type: Patients must have undergone a craniotomy to remove the tumor. Timeframe: The surgery must have occurred between the years 2016 and 2024

Who cannot take part

  • Exclusion CriteriaPatients will be excluded from the study if they meet any of the following conditions:; Recurrent Cases: Patients with a recurrent meningioma (rather than a first-time surgery); Emergency Cases: Patients requiring an emergency craniotomy. Pregnancy: Any patient who is pregnant. Major Complications: Patients who experienced cardiac arrest during the surgery

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Project Summary: Retrospective Cohort Study

Read full original descriptionShow less

1. Core ObjectiveThe primary goal is to determine if the volume of Hydroxyethyl Starch (HES) 130/0.4 (specifically Voluven® or Volulyte®) administered during the removal of giant meningiomas (tumors > 5 cm) increases the risk of postoperative complications. 2. Research Question

Does the volume of intraoperative HES solution influence the rate of re-bleeding (requiring a second surgery within 48 hours) or the development of Acute Kidney Injury (AKI) within 7 days after the initial craniotomy?Outcomes: 3. Outcomes Primary: Incidence of re-bleeding at the tumor bed requiring re-operation within 48 hours Secondary: New-onset postoperative AKI within 7 days (defined by KDIGO criteria)

The 2 groups in the trial

  • Exposed Group

    Patients who received HES during surgery

    Treatment: exposure to Hydroxyethyl Starch (HES) Voluven® or Volulyte® 130/0.4

  • Non-Exposed Group

    Patients who did not receive HES (received only crystalloids or other fluids).

    Treatment: exposure to Hydroxyethyl Starch (HES) Voluven® or Volulyte® 130/0.4

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy: A Retrospective Cohort Study
Record updated
17 March 2026